Sernova Corp.
TSX:SVA.TOBiotechnology
Healthcare
$0.14 -5.88%
-$0.01 today
- Market cap
- $50.98M
- Beta
- 0.66
- P/E (TTM)
- -4.7
- EPS (TTM)
- -$0.03
52W Low $0.12High $0.21
Volume 0.55M
Average 0.12M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$10.91M
FY 2025 · Annual
Investing Cash Flow
$24,958.00
FY 2025 · Annual
-99.8% YoYFinancing Cash Flow
$5.14M
FY 2025 · Annual
+1.3% YoYCash Flow Statement
CAD
Metric | FY2021 Oct 2021 | FY2022 Oct 2022 | FY2023 Oct 2023 | FY2024 Oct 2024 | FY2025 Oct 2025 |
|---|---|---|---|---|---|
| Net Income | (6.97M) | (24.42M) | (39M) | (32.19M) | (15.74M) |
| Depreciation & Amortization | 267.2K | 440K | 445.55K | 540.28K | 342.59K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | (70K) |
| Stock-Based Compensation | 218.4K | 7.45M | 3.9M | 1.75M | 2.3M |
| Change in Working Capital | 517.56K | 2.95M | 4.99M | 11.16M | 1.74M |
| Accounts Receivables | (89.8K) | (195.04K) | 229.7K | 561.85K | 175.47K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 607.35K | 3.14M | 4.76M | 10.6M | 1.56M |
| Other Non-Cash Items | (881.36K) | (838.57K) | (676.34K) | (150.48K) | 523.74K |
| Operating Cash Flow | (6.84M) | (14.42M) | (30.34M) | (18.9M) | (10.91M) |
| Capital Expenditures | (17.23K) | (329K) | (99.26K) | 0 | (3) |
| Acquisitions (Net) | 0 | 46M | 0 | 0 | 24.96K |
| Purchases of Investments | 0 | (59M) | (18.05M) | 0 | 0 |
| Sales of Investments | 0 | 13M | 52.97M | 11.08M | 0 |
| Other Investing Activities | (211.55K) | (46.01M) | (35.3K) | 35.3K | 0 |
| Investing Cash Flow | (228.78K) | (46.34M) | 34.78M | 11.12M | 24.96K |
| Debt Repayment | (28K) | (168.56K) | (171.93K) | (169.23K) | 4.94M |
| Common Stock Issued | 21.13M | 20.28M | 0 | 4.96M | 248.64K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 9.9M | 16.55M | 675.39K | 277.17K | (47.93K) |
| Financing Cash Flow | 31M | 36.66M | 503.46K | 5.07M | 5.14M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 23.92M | (24.1M) | 4.95M | (2.71M) | (5.75M) |
| Free Cash Flow | (6.86M) | (14.75M) | (30.44M) | (18.9M) | (10.91M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$15.7M
+ D&A$342.6K
+ Stock-Based Comp$2.3M
- Deferred Tax-$70.0K
+ Working Capital$1.7M
+ Other Non-Cash$523.7K
= Operating Cash Flow-$10.9M
- Capex-$3
= Free Cash Flow-$10.9M
Analysis
FY2025 free cash flow is -$10.9M. FCF conversion is 69.3% of net income. Operating cash flow was -$10.9M, with capex of -$3. The largest bridge item is Stock-Based Comp at $2.3M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
No filings found.
Does SVA.TO generate free cash flow?
Sernova Corp. (SVA.TO) generated -$10.91M of free cash flow in fiscal 2025.
How much operating cash flow does SVA.TO produce?
Operating cash flow was -$10.91M, before capital expenditures of $3.00.
Continue the stock analysis
Jump to another research area for this company.